Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsAn AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.
Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.
Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms
Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms
Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies
Young Adults With Glomerular Disease May Require Distinct Care
Q4 2025 Recap: Nephrology News and Updates
1.
Life quality after childhood cancer is quantifiable thanks to outcome indicators.
2.
"We Caught It Early": Advantage or Disadvantage?
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
A protein with new anticancer activity has been identified
5.
Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients
1.
How HLH is Revolutionizing Healthcare
2.
Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights
3.
Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions
4.
Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer
5.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
4.
Navigating the Complexities of Ph Negative ALL - Part X
5.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge